Drug Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Adverse Drug Reactions
Study Presented at ACC Shows Treatment With ISIS 301012 Added to Statins for Only 5 Weeks Results in 75% of Patients Achieving LDL-C Levels Less Than 100 mg/dL and 50% of Patients Achieving LDL-C Level
April 10th, 2007
Isis Pharmaceuticals, Inc. (NASDAQ:ISIS) announced new results from its Phase 2 clinical trial of ISIS 301012 coadministered with statins presented today at the American College of Cardiology Annual Scientific Session (ACC) in New Orleans. In the study, patients with high cholesterol were treated for five weeks with up to 400 mg/week of ISIS 301012 added to ongoing stable doses of statins. Data from this study for dose cohorts through 300 mg/week were previously reported. In the 400 mg/week cohort, ISIS 301012 was well tolerated, and patients dosed per protocol experienced statistically significant median improvements in apoB-100, LDL-cholesterol (LDL-C), and triglycerides (TG) of 51%,...
Source: Drug Law Weekly (2007-04-10)
|
